NextCure, Inc. Share Price
NXTCNextCure, Inc. Stock Performance
Open $9.52 | Prev. Close $9.96 | Circuit Range N/A |
Day Range $9.52 - $9.58 | Year Range $0.34 - $15.61 | Volume 451 |
Average Traded $9.56 |
NextCure, Inc. Share Price Chart
About NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
NextCure, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
27-Apr-26 | $10.44 | $9.96 | -9.54% |
24-Apr-26 | $11.50 | $11.01 | -8.33% |
23-Apr-26 | $11.01 | $12.01 | -0.29% |
22-Apr-26 | $10.57 | $12.04 | +7.83% |
21-Apr-26 | $11.84 | $11.17 | -14.93% |
20-Apr-26 | $12.09 | $13.13 | +25.05% |
17-Apr-26 | $10.90 | $10.50 | -5.70% |